Pulmatrix, a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary diseases, said it received two new patents from the US Patent and Trademark Office.
“The first new patent expands the potential of Pulmatrix’s technology for delivering drugs directly to the lungs,” said the company.
“Pulmatrix has developed a dry powder that ‘flies’ easily through the airways and can deliver a wide range of types of drugs.
“The technology significantly increases the efficiency of drug delivery and reduces side effects compared to existing approaches.”
The second new patent expands protections for Pulmatrix’s PUR0200 drug candidate for chronic obstructive pulmonary disease (COPD).